Table 1.

Characteristics of studies

Study	Condition	Duration (weeks)	Celecoxib treatment			Comparator treatment#
			No. of subjects	Total daily dose (mg)	Dosing regime	No. of subjects	Treatment
Solomon et al. (Ref 6)	P	145-161	1356	400 800	BD	679	Pl
CLASS (White et al., Ref 12)*	OA/RA	52	3987	800	BD	3981	lb, Di
Pfizer (Ref 15)	AD	52	285	400	BD	140	Pl
McKenna et al. (Ref 16)	OA	6	201	200	BD	399	Pl, Di
PreSAP (Levin, Ref 17)	P	156	933	800	OD	628	Pl
Geba et al. (Ref 18)	OA	6	97	200	OD	94	Para

RA, rheumatoid arthritis; OA, osteoarthritis; AD, Alzheimer's disease; P, prevention of colorectal adenoma in high risk subjects; lb, ibuprofen; Di, diclofenac; Pl, placebo; Para, paracetamol; CV, cardiovascular; OD, once daily; BD, twice daily; PreSAP, Prevention of Colorectal Sporadic Adenomatous Polyps

^*For the CLASS (Celecoxib Long-term Arthritis Safety Study) trial, the findings documented in White et al. (Ref ¹²) were used in the meta-analysis